inovmedИнновационная медицина КубаниInnovative Medicine of Kuban2541-9897Scientific Research Institute – Ochapovsky Regional Clinical Hospital No. 110.35401/2541-9897-2025-10-2-127-134inovmed-1183Research ArticleЛЕКЦИИLECTURESЗначение КТ в диагностике колита как осложнения терапевтического лечения онкологических пациентовRole of Computed Tomography in Diagnosis of Colitis as a Complication of Cancer Therapyhttps://orcid.org/0000-0002-6845-5613ЗябловаЕ. И.ZyablovaE. I.

Зяблова Елена Игоревна - д. м. н., доцент, заведующая рентгенологическим отделением, НИИ – ККБ № 1 им. проф. С.В. Очаповского; заведующая кафедрой лучевой диагностики № 2, КубГМУ; главный внештатный рентгенолог МЗ Краснодарского края.

350086, Краснодар, ул. 1 Мая, 167

Elena I. Zyablova - Dr. Sci. (Med.), Associate Professor, Head of the Radiology Unit, Scientific Research Institute – Ochapovsky Regional Clinical Hospital No. 1; Head of the Diagnostic Radiology Department No. 2, Kuban State Medical University; Chief Nonstaff Radiologist of the Ministry of Health of the Krasnodar Region.

ulitsa 1 Maya 167, Krasnodar, 350901

elenazyablova@inbox.ruhttps://orcid.org/0009-0005-3227-3120АгуринаН. В.AgurinaN. V.

Агурина Наталья Владимировна - ассистент кафедры лучевой диагностики № 2, КубГМУ; врач-рентгенолог рентгеновского отделения, НИИ – ККБ № 1 им. проф. С.В. Очаповского.

Краснодар

Natalia V. Agurina - Assistant Professor at the Diagnostic Radiology Department No. 2, Kuban State Medical University; Radiologist, Radiology Unit, Scientific Research Institute – Ochapovsky Regional Clinical Hospital No. 1.

Krasnodar

https://orcid.org/0000-0003-0572-1395ПорхановВ. А.PorhanovV. A.

Порханов Владимир Алексеевич - д. м. н., профессор, академик РАН; главный врач, НИИ – ККБ № 1 им. проф. С.В. Очаповского; заведующий кафедрой онкологии с курсом торакальной хирургии ФПК и ППС, КубГМУ.

Краснодар

Vladimir A. Porhanov - Dr. Sci. (Med.), Professor, Academician of the Russian Academy of Sciences, Chief Physician, Scientific Research Institute – Ochapovsky Regional Clinical Hospital No. 1; Head of the Oncology Department with the Thoracic Surgery Course, Faculty of Continuing Professional Development and Retraining, Kuban State Medical University.

Krasnodar

Научно-исследовательский институт – Краевая клиническая больница № 1 им. проф. С.В. Очаповского; Кубанский государственный медицинский университетРоссияScientific Research Institute – Ochapovsky Regional Clinical Hospital No. 1; Kuban State Medical UniversityRussian Federation202530062025102127134Copyright © Зяблова Е.И., Агурина Н.В., Порханов В.А., 20252025Зяблова Е.И., Агурина Н.В., Порханов В.А.Zyablova E.I., Agurina N.V., Porhanov V.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.innovmedkub.ru/jour/article/view/1183

Лекарственная терапия является неотъемлемой частью лечения онкологических заболеваний, однако наряду с положительным воздействием на опухолевые клетки, она может оказывать негативное влияние на здоровые ткани организма. Различные виды лечения и противоопухолевые препараты способны вызвать колит, осложнения которого могут иметь серьезные последствия для пациентов, вплоть до летального исхода.

Осведомленность и понимание особенностей визуализации колита, возникающего на фоне лекарственной терапии у онкологических пациентов, помогут на ранних стадиях выявлять эти осложнения, что, в свою очередь, улучшит ведение пациентов и результаты лечения.

Drug therapy is an integral part of cancer treatment, which, despite its positive effects on tumor cells, can negatively affect healthy body tissues. Various treatments and antitumor drugs can cause colitis. Its complications can be serious and even result in death. Awareness and knowledge of imaging features of drug-induced colitis in cancer patients can assist in early detection of its complications and thus improve patient management and outcomes.

КТколитнежелательные явленияиммунотерапияхимиотерапиятаргетная терапияcomputed tomographycolitisadverse eventsimmunotherapychemotherapytargeted therapyReferencesViswanathan C, Truong MT, Sagebiel TL, et al. Abdominal and pelvic complications of nonoperative oncologic therapy. Radiographics. 2014;34(4):941–961. PMID: 25019433. https://doi.org/10.1148/rg.344140082Viswanathan C, Truong MT, Sagebiel TL, et al. Abdominal and pelvic complications of nonoperative oncologic therapy. Radiographics. 2014;34(4):941–961. PMID: 25019433. https://doi.org/10.1148/rg.344140082Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158–168. PMID: 29320654. https://doi.org/10.1056/NEJMra1703481Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158–168. PMID: 29320654. https://doi.org/10.1056/NEJMra1703481Kim KW, Ramaiya NH, Krajewski KM, et al. Ipilimumab-associated colitis: CT findings. AJR Am J Roentgenol. 2013;200(5):W468–W474. PMID: 23718569. https://doi.org/10.2214/AJR.12.9751Kim KW, Ramaiya NH, Krajewski KM, et al. Ipilimumab-associated colitis: CT findings. AJR Am J Roentgenol. 2013;200(5):W468–W474. PMID: 23718569. https://doi.org/10.2214/AJR.12.9751Freeman HJ. Colitis associated with biological agents. World J Gastroenterol. 2012;18(16):1871–1874. PMID: 22563166. PMCID: PMC3337561. https://doi.org/10.3748/wjg.v18.i16.1871Freeman HJ. Colitis associated with biological agents. World J Gastroenterol. 2012;18(16):1871–1874. PMID: 22563166. PMCID: PMC3337561. https://doi.org/10.3748/wjg.v18.i16.1871Ibarra Rovira J, Thirumurthi S, Taggart M, et al. Role of abdominal and pelvic CT scans in diagnosis of patients with immunotherapy-induced colitis. J Immunother Precis Oncol. 2022;5(2):32–36. PMID: 35664090. PMCID: PMC9153249. https://doi.org/10.36401/JIPO-21-21Ibarra Rovira J, Thirumurthi S, Taggart M, et al. Role of abdominal and pelvic CT scans in diagnosis of patients with immunotherapy-induced colitis. J Immunother Precis Oncol. 2022;5(2):32–36. PMID: 35664090. PMCID: PMC9153249. https://doi.org/10.36401/JIPO-21-21Naing A, Hajjar J, Gulley JL, et al. Strategies for improving the management of immune-related adverse events. J Immunother Cancer. 2020;8(2):e001754. PMID: 33310772. PMCID: PMC7735083. https://doi.org/10.1136/jitc-2020-001754Naing A, Hajjar J, Gulley JL, et al. Strategies for improving the management of immune-related adverse events. J Immunother Cancer. 2020;8(2):e001754. PMID: 33310772. PMCID: PMC7735083. https://doi.org/10.1136/jitc-2020-001754Ramos-Casals M, Brahmer JR, Callahan MK, et al. Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers. 2020;6(1):38. PMID: 32382051. PMCID: PMC9728094. https://doi.org/10.1038/s41572-020-0160-6Ramos-Casals M, Brahmer JR, Callahan MK, et al. Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers. 2020;6(1):38. PMID: 32382051. PMCID: PMC9728094. https://doi.org/10.1038/s41572-020-0160-6Marthey L, Mateus C, Mussini C, et al. Cancer immunotherapy with anti-CTLA-4 monoclonal antibodies induces an inflammatory bowel disease. J Crohns Colitis. 2016;10(4):395–401. PMID: 26783344. PMCID: PMC4946758. https://doi.org/10.1093/ecco-jcc/jjv227Marthey L, Mateus C, Mussini C, et al. Cancer immunotherapy with anti-CTLA-4 monoclonal antibodies induces an inflammatory bowel disease. J Crohns Colitis. 2016;10(4):395–401. PMID: 26783344. PMCID: PMC4946758. https://doi.org/10.1093/ecco-jcc/jjv227Gupta A, De Felice KM, Loftus EV Jr, Khanna S. Systematic review: colitis associated with anti-CTLA-4 therapy. Aliment Pharmacol Ther. 2015;42(4):406–417. PMID: 26079306. https://doi.org/10.1111/apt.13281Gupta A, De Felice KM, Loftus EV Jr, Khanna S. Systematic review: colitis associated with anti-CTLA-4 therapy. Aliment Pharmacol Ther. 2015;42(4):406–417. PMID: 26079306. https://doi.org/10.1111/apt.13281Beck KE, Blansfield JA, Tran KQ, et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol. 2006;24(15):2283–2289. PMID: 16710025. PMCID: PMC2140223. https://doi.org/10.1200/JCO.2005.04.5716Beck KE, Blansfield JA, Tran KQ, et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol. 2006;24(15):2283–2289. PMID: 16710025. PMCID: PMC2140223. https://doi.org/10.1200/JCO.2005.04.5716Itani M, Menias CO, Mellnick VM, et al. Imaging of abdominal and pelvic infections in the cancer patient. Abdom Radiol (NY). 2021;46(6):2920–2941. PMID: 33386914. PMCID: PMC7778421. https://doi.org/10.1007/s00261-020-02896-7Itani M, Menias CO, Mellnick VM, et al. Imaging of abdominal and pelvic infections in the cancer patient. Abdom Radiol (NY). 2021;46(6):2920–2941. PMID: 33386914. PMCID: PMC7778421. https://doi.org/10.1007/s00261-020-02896-7Barina AR, Bashir MR, Howard BA, Hanks BA, Salama AK, Jaffe TA. Isolated recto-sigmoid colitis: a new imaging pattern of ipilimumab-associated colitis. Abdom Radiol (NY). 2016;41(2):207–214. PMID: 26867901. https://doi.org/10.1007/s00261-015-0560-3Barina AR, Bashir MR, Howard BA, Hanks BA, Salama AK, Jaffe TA. Isolated recto-sigmoid colitis: a new imaging pattern of ipilimumab-associated colitis. Abdom Radiol (NY). 2016;41(2):207–214. PMID: 26867901. https://doi.org/10.1007/s00261-015-0560-3Pozzessere C, Mazini B, Omoumi P, et al. Immune-related adverse events induced by immune checkpoint inhibitors and CAR-T cell therapy: a comprehensive imaging-based review. Cancers (Basel). 2024;16(14):2585. PMID: 39061225. PMCID: PMC11274393. https://doi.org/10.3390/cancers16142585Pozzessere C, Mazini B, Omoumi P, et al. Immune-related adverse events induced by immune checkpoint inhibitors and CAR-T cell therapy: a comprehensive imaging-based review. Cancers (Basel). 2024;16(14):2585. PMID: 39061225. PMCID: PMC11274393. https://doi.org/10.3390/cancers16142585Зяблова Е.И., Нефедова Л.Н., Порханов В.А. Лучевая диагностика иммунотерапевтических осложнений. Онкологический журнал: лучевая диагностика, лучевая терапия. 2020;3(3):44–53. https://doi.org/10.37174/2587-7593-2020-3-3-44-53Zyablova EI, Nefedova LN, Porkhanov VA. Radiological imaging of adverse events to immunotherapy. Journal of Oncology: Diagnostic Radiology and Radiotherapy. 2020;3(3):44–53. (In Russ.). https://doi.org/10.37174/2587-7593-2020-3-3-44-53Macari M, Balthazar EJ. CT of bowel wall thickening: significance and pitfalls of interpretation. AJR Am J Roentgenol. 2001;176(5):1105–1116. PMID: 11312162. https://doi.org/10.2214/ajr.176.5.1761105Macari M, Balthazar EJ. CT of bowel wall thickening: significance and pitfalls of interpretation. AJR Am J Roentgenol. 2001;176(5):1105–1116. PMID: 11312162. https://doi.org/10.2214/ajr.176.5.1761105Latella G, Vernia P, Viscido A, et al. GI distension in severe ulcerative colitis. Am J Gastroenterol. 2002;97(5):1169–1175. PMID: 12014723. https://doi.org/10.1111/j.1572-0241.2002.05691.xLatella G, Vernia P, Viscido A, et al. GI distension in severe ulcerative colitis. Am J Gastroenterol. 2002;97(5):1169–1175. PMID: 12014723. https://doi.org/10.1111/j.1572-0241.2002.05691.xBrahmer JR, Abu-Sbeih H, Ascierto PA, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J Immunother Cancer. 2021;9(6):e002435. PMID: 34172516. PMCID: PMC8237720. https://doi.org/10.1136/jitc-2021-002435Brahmer JR, Abu-Sbeih H, Ascierto PA, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J Immunother Cancer. 2021;9(6):e002435. PMID: 34172516. PMCID: PMC8237720. https://doi.org/10.1136/jitc-2021-002435Horvat TZ, Adel NG, Dang TO, et al. Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center. J Clin Oncol. 2015;33(28):3193–3198. PMID: 26282644. PMCID: PMC5087335. https://doi.org/10.1200/JCO.2015.60.8448Horvat TZ, Adel NG, Dang TO, et al. Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center. J Clin Oncol. 2015;33(28):3193–3198. PMID: 26282644. PMCID: PMC5087335. https://doi.org/10.1200/JCO.2015.60.8448Beck KE, Blansfield JA, Tran KQ, et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol. 2006;24(15):2283–2289. PMID: 16710025. PMCID: PMC2140223. https://doi.org/10.1200/JCO.2005.04.5716Beck KE, Blansfield JA, Tran KQ, et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol. 2006;24(15):2283–2289. PMID: 16710025. PMCID: PMC2140223. https://doi.org/10.1200/JCO.2005.04.5716Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–723. Published correction appears in N Engl J Med. 2010;363(13):1290. PMID: 20525992. PMCID: PMC3549297. https://doi.org/10.1056/NEJ-Moa1003466Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–723. Published correction appears in N Engl J Med. 2010;363(13):1290. PMID: 20525992. PMCID: PMC3549297. https://doi.org/10.1056/NEJ-Moa1003466Torrisi JM, Schwartz LH, Gollub MJ, Ginsberg MS, Bosl GJ, Hricak H. CT findings of chemotherapy-induced toxicity: what radiologists need to know about the clinical and radiologic manifestations of chemotherapy toxicity. Radiology. 2011;258(1):41-56. PMID: 21183492. https://doi.org/10.1148/radiol.10092129Torrisi JM, Schwartz LH, Gollub MJ, Ginsberg MS, Bosl GJ, Hricak H. CT findings of chemotherapy-induced toxicity: what radiologists need to know about the clinical and radiologic manifestations of chemotherapy toxicity. Radiology. 2011;258(1):41-56. PMID: 21183492. https://doi.org/10.1148/radiol.10092129Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, November 27, 2017. https://ctep.cancer.gov/proto-coldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_8.5x11.pdfCommon Terminology Criteria for Adverse Events (CTCAE) Version 5.0, November 27, 2017. https://ctep.cancer.gov/proto-coldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_8.5x11.pdf

The authors declare that there are no conflicts of interest present.